Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review.

Abstract:

:Bronchiectasis occurs as a result of a vicious circle consisting of an impaired mucociliary transport system, inflammation, and infection and repair of the airways. Damage to the mucociliary system prevents secretion elimination and facilitates bacterial growth and bronchial inflammation. To facilitate mucociliary clearance, current guidelines recommend the use of hypertonic saline (HS) solutions in patients with bronchiectasis not secondary to cystic fibrosis (CF), although the evidence of efficacy in this pathology is sparse. A high percentage of patients with CF and bronchiectasis tolerate HS solutions, but often patients report cough, dyspnoea, throat irritation, or salty taste after inhalation. These adverse effects negatively impact adherence to treatment, which sometimes must be discontinued. Some studies have shown that the addition of hyaluronic acid increases the tolerability of HS solutions, both in patients with CF and in bronchiectasis of other etiologies. We aimed to review the benefits and safety of HS solutions in patients with bronchiectasis. The reviews of this paper are available via the supplemental material section.

journal_name

Ther Adv Respir Dis

authors

Máiz Carro L,Martínez-García MA

doi

10.1177/1753466619866102

subject

Has Abstract

pub_date

2019-01-01 00:00:00

pages

1753466619866102

eissn

1753-4658

issn

1753-4666

journal_volume

13

pub_type

杂志文章,评审
  • Endoscopic lung volume reduction coil treatment in patients with very low FEV1: an observational study.

    abstract:BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted t...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466618760133

    authors: Simon M,Harbaum L,Oqueka T,Kluge S,Klose H

    更新日期:2018-01-01 00:00:00

  • Biomarkers in the diagnosis of pleural diseases: a 2018 update.

    abstract::The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. Three paradigmatic examples are heart failure, tuberculosis and, particularly, malignancy. An elevated PF concentration of the amino-terminal fragment of probrain natriuretic peptide (...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466618808660

    authors: Porcel JM

    更新日期:2018-01-01 00:00:00

  • Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies.

    abstract:BACKGROUND:Direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) therapy has been approved for sepsis-associated acute respiratory distress syndrome, but its efficacy for other rapidly progressive interstitial pneumonias (RPIPs) is unclear. The purpose of this study was to examine the efficacy of PM...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465817708950

    authors: Ichiyasu H,Horio Y,Masunaga A,Migiyama Y,Sakamoto Y,Jodai T,Ideguchi H,Okabayashi H,Hamada S,Yoshida C,Hirosako S,Okamoto S,Kohrogi H

    更新日期:2017-07-01 00:00:00

  • Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.

    abstract:OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/1753465813497527

    authors: Bjermer L,Rosenborg J,Bengtsson T,Lötvall J

    更新日期:2013-10-01 00:00:00

  • Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.

    abstract:RATIONALE:Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with different levels of symptom severity. This study compared treatment responses ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620968500

    authors: Vogelmeier CF,Kerwin EM,Bjermer LH,Tombs L,Jones PW,Boucot IH,Naya IP,Lipson DA,Compton C,Barnes N,Maltais F

    更新日期:2020-01-01 00:00:00

  • A comprehensive analysis of microRNAs as diagnostic biomarkers for asthma.

    abstract:BACKGROUND:It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma. METHODS:Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted acco...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620981863

    authors: Xu L,Yi M,Tan Y,Yi Z,Zhang Y

    更新日期:2020-01-01 00:00:00

  • The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.

    abstract::In recent years in the management of pulmonary arterial hypertension (PAH), endothelin receptor antagonists (ERAs) represent a well-established class of therapeutic agents with clear beneficial effects. Macitentan (Opsumit®), a dual ERA optimized for efficacy and safety, is the newest drug in the class. Macitentan pre...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465814530182

    authors: Steriade A,Seferian A,Jaïs X,Savale L,Jutant EM,Parent F,Sitbon O,Humbert M,Simonneau G,Montani D

    更新日期:2014-06-01 00:00:00

  • Electronic cigarettes: an aid in smoking cessation, or a new health hazard?

    abstract::The issue of electronic cigarettes is one of the most controversial topics in public health. There is intense debate and dividing opinions about their use patterns, health effects and association with smoking. This is expected since they were only recently introduced to the market and they refer to a harm-reduction ap...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465817744960

    authors: Farsalinos K

    更新日期:2018-01-01 00:00:00

  • Surfactant protein D: a lung specific biomarker in COPD?

    abstract::A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synth...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808088903

    authors: Sin DD,Pahlavan PS,Man SF

    更新日期:2008-04-01 00:00:00

  • The influence of speleotherapy combined with pulmonary rehabilitation on functional fitness in older adults - preliminary report.

    abstract:OBJECTIVE:Our aim was to determine the influence of pulmonary rehabilitation conducted in therapeutic salt mine chambers on the functional fitness of older adults. METHODS:The study included 22 individuals of age >65 years with chronic respiratory conditions. The patients underwent the Fullerton test before and after ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620926952

    authors: Mętel S,Kostrzon M,Adamiak J,Gattner H,Kościelecka D,Sosulska A,Szczygieł E,Golec J

    更新日期:2020-01-01 00:00:00

  • Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

    abstract::Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465816669662

    authors: Kappen JH,Durham SR,Veen HI,Shamji MH

    更新日期:2017-01-01 00:00:00

  • Leukotriene modifiers in the treatment of asthma in children.

    abstract::Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Inflammation is the most important component of asthma and inhaled corticosteroids (ICS) are recommended as the first line controller treatment for patients of all ages. Treatment with corticosteroids ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809348014

    authors: del Giudice MM,Pezzulo A,Capristo C,Alterio E,Caggiano S,de Benedictis D,Capristo AF

    更新日期:2009-10-01 00:00:00

  • Current best practice in pulmonary rehabilitation for chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812444712

    authors: de Blasio F,Polverino M

    更新日期:2012-08-01 00:00:00

  • Tolerability of inhaled N-chlorotaurine in humans: a double-blind randomized phase I clinical study.

    abstract:BACKGROUND:N-chlorotaurine (NCT), a long-lived oxidant produced by human leukocytes, can be synthesized chemically and used topically as a well-tolerated antiseptic to different body regions including sensitive ones. The aim of this study was to test the tolerability of inhaled 1% NCT in aqueous solution upon repeated ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/1753466618778955

    authors: Arnitz R,Stein M,Bauer P,Lanthaler B,Jamnig H,Scholl-Bürgi S,Stempfl-Al-Jazrawi K,Ulmer H,Baumgartner B,Embacher S,Geisler S,Gostner JM,Müllinger B,Kälz B,Nagl M

    更新日期:2018-01-01 00:00:00

  • Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis.

    abstract:BACKGROUND:Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is well known as a life-threatening condition during its clinical course. However, the clinical features and prognosis in AE of unclassifiable idiopathic interstitial pneumonia (AE-UCIIP) remain to be elucidated. The aim of this study was to clarif...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620935774

    authors: Enomoto N,Naoi H,Aono Y,Katsumata M,Horiike Y,Yasui H,Karayama M,Hozumi H,Suzuki Y,Furuhashi K,Fujisawa T,Inui N,Nakamura Y,Suda T

    更新日期:2020-01-01 00:00:00

  • An immunological overview of allergen specific immunotherapy -- subcutaneous and sublingual routes.

    abstract::Allergen-specific immunotherapy remains the most likely effective treatment modality for allergic disorders by targeting the underlying immune mechanisms and possibly causing modifications in the disease course, as well as treating the symptoms. Treatment and compliance experiences been gained over nearly a century in...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809349522

    authors: Ozdemir C

    更新日期:2009-10-01 00:00:00

  • Efficacy and safety profile of autologous blood versus talc pleurodesis for malignant pleural effusion: a randomized controlled trial.

    abstract:BACKGROUND:Autologous blood is a novel, high-efficacy sclerosant for treatment of malignant pleural effusion (MPE), similar to tetracycline. There has been no comparative data between autologous blood and a worldwide sclerosant like talc. We aimed to compare the effectiveness of autologous blood versus talc pleurodesis...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1753466618816625

    authors: Keeratichananont W,Kaewdech A,Keeratichananont S

    更新日期:2018-01-01 00:00:00

  • Therapeutic perspectives in bronchial vascular remodeling in COPD.

    abstract::COPD may be characterized by significant changes in airway mucosal blood vessels, which may contribute to bronchial airway remodeling. The airway wall is more vascularized in COPD patients than in healthy subjects, though this phenomenon is less evident than in asthmatic patients. The vascular mucosal changes in the a...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808092339

    authors: Zanini A,Chetta A,Olivieri D

    更新日期:2008-06-01 00:00:00

  • Early predictors for mechanical ventilation in COVID-19 patients.

    abstract:OBJECTIVE:To identify potential predictors for invasive and non-invasive mechanical ventilation in coronavirus disease 2019 (COVID-19) patients. METHODS:This study retrospectively analyzes data of 516 patients with confirmed COVID-19, who were categorized into three groups based on which mechanical ventilation method ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620963017

    authors: Li W,Lin F,Dai M,Chen L,Han D,Cui Y,Pan P

    更新日期:2020-01-01 00:00:00

  • Current approaches to pharmacotherapy for smoking cessation.

    abstract::It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smokin...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809353768

    authors: Hudmon KS,Corelli RL,Prokhorov AV

    更新日期:2010-02-01 00:00:00

  • An update on the use of indacaterol in patients with COPD.

    abstract::Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465810387810

    authors: Brienza NS,Amor-Carro O,Ramos-Barbón D

    更新日期:2011-02-01 00:00:00

  • Therapies for interstitial lung disease: past, present and future.

    abstract::As our understanding of the pathobiology and natural history of the various forms of interstitial lung disease (ILD) has evolved, so have our approaches to treating this heterogeneous group of lung disorders. The earliest pharmacologic agents used to treat various forms of ILD were corticosteroids, and corticosteroids...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808096948

    authors: Kim R,Meyer KC

    更新日期:2008-10-01 00:00:00

  • Improving home oxygen therapy in patients with interstitial lung diseases: application of a noninvasive ventilation device.

    abstract:BACKGROUND:Proper adjustment of arterial oxygen saturation (SaO2) during daily activities in patients with interstitial lung disease (ILD) requiring long-term oxygen therapy is challenging. Given the multifactorial nature of the limited exercise tolerance in patients with ILDs, the isolated use of oxygen therapy may no...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620963027

    authors: Cuerpo S,Palomo M,Hernández-González F,Francesqui J,Albacar N,Hernández C,Blanco I,Embid C,Sellares J

    更新日期:2020-01-01 00:00:00

  • Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.

    abstract::Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different extrarticular manifestations involving heart, lungs and kidneys. In recent years there has been a growing awareness of the central role played by the lungs in the onset and progression of RA. In particular interstitial lung dise...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465816668780

    authors: Picchianti Diamanti A,Markovic M,Argento G,Giovagnoli S,Ricci A,Laganà B,D'Amelio R

    更新日期:2017-01-01 00:00:00

  • The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.

    abstract::Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto® or Stiolto® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenocep...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466619843426

    authors: Derom E,Brusselle GG,Joos GF

    更新日期:2019-01-01 00:00:00

  • Factors determining the quality of life of patients with COPD in primary care.

    abstract:OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regar...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究

    doi:10.1177/1753465807086097

    authors: Miravitlles M,Molina J,Naberan K,Cots JM,Ros F,Llor C,EVOCA study.

    更新日期:2007-12-01 00:00:00

  • Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

    abstract::Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812459899

    authors: Hurley M,Smyth A

    更新日期:2012-12-01 00:00:00

  • Clinical and anti-inflammatory effects of ultra-short preseasonal vaccine to Parietaria in asthma.

    abstract:OBJECTIVE:The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of i...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465813476564

    authors: Scichilone N,Scalici V,Arrigo R,Bellia V

    更新日期:2013-08-01 00:00:00

  • Community versus hospital-acquired pneumonia in patients requiring extracorporeal membrane oxygenation.

    abstract:BACKGROUND:Bacterial pneumonia is a major cause of acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) support. However, it is unknown whether the type of pneumonia, community-acquired pneumonia (CAP) versus hospital-acquired pneumonia (HAP), should be considered when predict...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466618821038

    authors: Park C,Na SJ,Chung CR,Cho YH,Suh GY,Jeon K

    更新日期:2019-01-01 00:00:00

  • Reporting of central airway obstruction on radiology reports and impact on bronchoscopic airway interventions and patient outcomes.

    abstract:BACKGROUND:Central airway obstruction (CAO) is a serious condition that affects patients with both benign and malignant diseases. Timely recognition of CAO is crucial for prompt intervention aimed at improving the symptoms and quality of life of these patients. The aim of this study is to evaluate the formal radiology ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465815620111

    authors: Harris K,Alraiyes AH,Attwood K,Modi K,Dhillon SS

    更新日期:2016-04-01 00:00:00